Figure 5 — Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection

Research Paper|Volume 15, Issue 11|pp. 5190–5214

Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection

Back to articleFigure 5(5 of 7)

100%

Figure 5.Cellular characteristics of immune subtypes. (A) Distribution of immune subtypes (ImmuC1-C6) across C1/C2 ccRCC patients. (B) Overall activity of immune cells in C1/C2 ccRCC patients. (C, D) Immune score and stromal score of C1/C2 ccRCC patients from TCGA and ICGC cohorts. (E–H) Tumor purity and CYT score of C1/C2 ccRCC patients from TCGA (E, G) and ICGC (F, H) cohorts. (I, J) Immune cell proportions of C1/C2 ccRCC patients from TCGA and ICGC cohorts separately. ^*padj < 0.05; ^**padj < 0.01; ^***padj < 0.001.